IRIS
NOZZA, SILVIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.681
NA - Nord America 1.954
EU - Europa 1.747
SA - Sud America 691
AF - Africa 56
OC - Oceania 5
Totale 7.134
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.831
SG - Singapore 1.090
CN - Cina 858
BR - Brasile 581
RO - Romania 340
HK - Hong Kong 334
SE - Svezia 273
IT - Italia 268
RU - Federazione Russa 242
DE - Germania 210
VN - Vietnam 165
FI - Finlandia 94
GB - Regno Unito 89
AR - Argentina 63
CA - Canada 62
IN - India 56
PL - Polonia 50
MX - Messico 49
AT - Austria 42
ID - Indonesia 42
BD - Bangladesh 31
FR - Francia 30
ZA - Sudafrica 29
NL - Olanda 27
ES - Italia 24
JP - Giappone 24
LT - Lituania 22
TR - Turchia 16
IQ - Iraq 15
EC - Ecuador 14
MA - Marocco 13
UA - Ucraina 11
IE - Irlanda 10
CO - Colombia 8
BE - Belgio 7
UY - Uruguay 7
UZ - Uzbekistan 7
AE - Emirati Arabi Uniti 6
EG - Egitto 6
KZ - Kazakistan 6
PK - Pakistan 6
PY - Paraguay 6
AU - Australia 5
CL - Cile 5
DO - Repubblica Dominicana 4
PH - Filippine 4
VE - Venezuela 4
IL - Israele 3
SA - Arabia Saudita 3
AZ - Azerbaigian 2
CH - Svizzera 2
GT - Guatemala 2
HN - Honduras 2
IR - Iran 2
JO - Giordania 2
KE - Kenya 2
NG - Nigeria 2
NP - Nepal 2
PE - Perù 2
RS - Serbia 2
TN - Tunisia 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BY - Bielorussia 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
GE - Georgia 1
GY - Guiana 1
KW - Kuwait 1
LB - Libano 1
NI - Nicaragua 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
SI - Slovenia 1
SN - Senegal 1
SY - Repubblica araba siriana 1
Totale 7.134
Salva come PNG Salva come JPEG
Città #
Singapore 558
Dallas 347
Hong Kong 332
Ashburn 222
Shanghai 187
Beijing 155
Hefei 151
New York 140
Munich 96
Los Angeles 91
Lawrence 79
Princeton 79
Milan 75
Moscow 66
São Paulo 66
Ho Chi Minh City 53
Helsinki 46
Boardman 42
Denver 42
Nuremberg 41
Warsaw 41
Cesano Boscone 33
Montreal 31
Turku 31
Stockholm 28
Hanoi 27
Santa Clara 27
London 26
Brooklyn 25
Orem 25
Poplar 24
Tokyo 24
Falkenstein 23
Chennai 22
Gatchina 22
Guangzhou 22
Seattle 22
St Petersburg 22
Vienna 20
Johannesburg 19
Amsterdam 18
Rio de Janeiro 18
Atlanta 17
Phoenix 17
Mexico City 16
Houston 15
Frankfurt am Main 14
Lappeenranta 14
Manchester 14
Brasília 13
Ankara 12
Belo Horizonte 12
Boston 12
Chicago 12
Perm 12
Shenzhen 12
Tianjin 12
Toronto 12
Jakarta 11
Nanjing 11
Council Bluffs 10
Dublin 10
Haiphong 10
Pune 10
Yekaterinburg 10
Da Nang 9
Querétaro 9
Biên Hòa 8
Mumbai 8
New Delhi 8
Porto Alegre 8
Romagnano Sesia 8
Brussels 7
Charlotte 7
Columbus 7
Goiânia 7
Guayaquil 7
Hải Dương 7
Nizhniy Novgorod 7
Rome 7
Tashkent 7
Turin 7
Baghdad 6
Busto Arsizio 6
Curitiba 6
Fortaleza 6
Paris 6
Pouso Alegre 6
Quito 6
Salvador 6
San Francisco 6
Sorocaba 6
St Louis 6
São Bernardo do Campo 6
The Dalles 6
Voronezh 6
Almaty 5
Boca 5
Borås 5
Buenos Aires 5
Totale 3.938
Salva come PNG Salva come JPEG
Nome #
The propensity for long-acting cabotegravir and rilpivirine every 2 months among HIV-infected people eligible for treatment 225
Monkeypox in a patient with undifferentiated connective tissue disease 217
Viral bloodstream detection in mpox patients: An observational multicentric study 195
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 133
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 110
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study 98
Allogeneic bone marrow transplantation in HIV people with hematological malignancies: Post-transplant cyclophosphamide to overcome the HLA-matching barrier 91
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 80
Characteristics of HIV pre-exposure prophylaxis users at first PrEP counselling visit: the CSL-PrEP cohort 77
A case of breakthrough mpox infection in an individual non-responder to MVA-BN vaccination 76
Human Monkeypox Experience in a Tertiary Level Hospital in Milan, Italy, between May and October 2022: Epidemiological Features and Clinical Characteristics 75
Meningococcus B Vaccination Effectiveness Against Neisseria gonorrhoeae Infection in People Living With HIV: A Case-Control Study 75
Failure of on-demand pre-exposure prophylaxis: the risk of HIV drug resistance 73
Enhanced immunological recovery with early start of antiretroviral therapy during acute or early HIV infection–results of Italian network of acute HIV infection (Inaction) retrospective study 73
Mpox Outbreak 2022: A Comparative Analysis of the Characteristics of Individuals Receiving MVA-BN Vaccination and People Diagnosed with Mpox Infection in Milan, Italy 72
Analytical treatment interruption in chronic HIV-1 infection: Time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study) 71
Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study) 71
Antiretroviral therapy in geriatric HIV patients: The GEPPO cohort study 70
Breakthrough monkeypox infection among individuals previously immunized with smallpox or monkeypox vaccination 69
Prior Neisseria meningitidis (Nm) proctitis does not prevent Neisseria gonorrhoeae (Ng) proctitis among men who have sex with men (MSM) 67
Monkeypox infection in a hemopoietic stem cell and heart transplant recipient 66
HIV-DNA undetectability during chronic HIV infection: Frequency and predictive factors 65
Beneficial effects of cART initiated during primary and chronic HIV-1 infection on immunoglobulin-expression of memory B-cell subsets 64
HIV viral load monitoring during monkeypox virus infection among people with HIV 63
Trends of Antimicrobial Susceptibility of Neisseria gonorrhoeae Isolates between 2012 and 2023: Results from an Open Italian Cohort 62
A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study 62
Beyond stigma: Monkeypox infection in a 27-year-old woman 61
Activating Killer Immunoglobulin Receptors and HLA-C: A successful combination providing HIV-1 control 61
Association of high-risk sexual behaviours with sexually transmitted infections among men who have sex with men living with HIV 60
Monkeypox infection among men who have sex with men: PCR testing on seminal fluids 60
Sexually Transmitted Enteric Infections in Men Who Have Sex With Men Living With HIV Over 8 Years of Follow-up 60
Monkeypox and pan-resistant Campylobacter spp infection in Entamoeba histolytica and Chlamydia trachomatis re-infection in a man who have sex with men 59
A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses 59
Mpox neutralising antibodies at 6 months from mpox infection or MVA-BN vaccination: a comparative analysis 59
Isolated monkeypox proctitis among men who have sex with men 58
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice 58
Rectal Lymphogranuloma venereum among Men who Have Sex with Men: 7 versus 21 Days Doxycycline Effectiveness 57
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort 57
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 57
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 57
High Propensity to Switch to Long-acting Injectable HIV PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men in Italy 55
Persistent ocular mpox infection in an immunocompetent individual 55
Late positivization of oropharyngeal, plasma, anal, semen, and urine specimens which tested negative at the time of mpox diagnosis 54
Anti-Tat immunity defines CD4 + T-cell dynamics in people living with HIV on long-term cART 54
HIV-NAAT use for early detection of HIV infection among high-risk men who have sex with men in Italy 53
Viral hepatitis and human papillomavirus vaccination during pre-exposure prophylaxis: factors associated with missed vaccination 53
Tick-borne encephalitis seroprevalence in northern Italy: a cross-sectional study on a randomly selected population 53
Sexually transmitted infections in men who have sex with men with tenofovir/emtricitabine- or cabotegravir-resistant HIV 53
Role of multi-site sampling in the diagnosis of human Monkeypox 52
VIRO-immunological outcomes after 13-valent pneumococcal vaccination in HIV-1-infected individuals on stable virological suppression 52
Prevalence and Risk Factors of Anal HPV Infection in MSM Living With HIV: Identifying the Target Groups to Prioritize for Immunization 52
Viral Hepatitis and Human Papillomavirus Vaccination during HIV Pre-Exposure Prophylaxis: Factors Associated with Missed Vaccination 51
One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART Study 51
Real-life use of cidofovir for the treatment of severe monkeypox cases 51
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 51
Proctitis and prostatitis by Neisseria meningitidis among MSM: A case series 50
B-cell subset alterations and correlated factors in HIV-1 infection 50
Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen 50
Antibiotic resistance among sexually transmitted infections: perspectives from clinical practice 49
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project. 49
Monotherapy with atazanavir as a simplification strategy: results from an observational study. 49
Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIV 49
Implementation of recombinant anti-herpes zoster vaccination in people living with HIV: a single-center experience 48
Increasing incidence and prevalence of metabolic syndrome in people living with HIV during the COVID-19 pandemic 47
Early Diagnosis and Linkage to Care: an Experience over 14 years of Point of Care Rapid HIV Testing 47
Two individuals with potential monkeypox virus reinfection 47
Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen 47
Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort 46
Dynamics of adaptive and innate immunity inpatients treated during primary human immunodeficiency virus infection: Results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial 46
Unified European support framework to sustain the HIV cascade of care for people living with HIV including in displaced populations of war-struck Ukraine 45
Ageing with HIV: a multidisciplinary review 45
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption 45
Maraviroc 150mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study 45
Differential dynamics of Epstein-Barr virus in individuals infected with human immunodeficiency virus-1 receiving intermittent interleukin-2 and antiretroviral therapy 44
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients 44
Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine 44
Awareness and perception of accuracy of the Undetectable=Untransmittable message (U=U) in Italy: results from a survey among PLWHA, infectious-diseases physicians and people having unprotected sex 42
Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression 42
Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022 41
Mpox in people with past infection or a complete vaccination course: a global case series 41
Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients 41
Estimated glomerular filtration rate trajectories in HIV-infected subjects treated with different ritonavir-boosted protease inhibitors and tenofovir disoproxil fumarate or abacavir 41
Multidrug-resistant Mycoplasma genitalium urethritis: successful eradication with sequential therapy 40
Clinical and laboratory predictors of mpox severity and duration: an Italian multicentre cohort study (mpox-Icona) 40
Immune recovery and T cell subset analysis during effective treatment with maraviroc 40
The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection. 40
Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy 40
Evaluation of analytical performance of the STANDARDTM M10 MPX/OPX assay for the simultaneous DNA detection and clade attribution of Monkeypox virus 39
Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT) 39
Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up 39
Pustulosis acuta generalisata following chemotherapy in an HIV-positive patient 39
Is statin preventing cancer in HIV-1 infected individuals? An inappropriate methodology is a more likely explanation: authors' reply 38
HIV-1-mediated insertional activation of STAT5B and BACH2 trigger viral reservoir in T regulatory cells 38
Doravirine associated with greater LDL cholesterol reduction in people with HIV switching antiretroviral regimens 37
Vaccines against Emerging Sexually Transmitted Infections: Current Preventive Tools and Future Perspectives 37
Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patients 37
Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection 37
Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected males 37
Rapid improvement of severe Mpox lesions with oral tecovirimat 36
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination 36
Totale 5.936
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.018
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.018
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202122 0 0 0 0 0 7 2 11 1 0 1 0
2021/202273 0 0 0 20 7 9 3 6 4 11 3 10
2022/2023469 178 99 20 2 1 42 48 56 9 5 4 5
2023/2024559 9 19 99 48 64 125 21 58 1 15 30 70
2024/20252.693 196 35 75 78 123 224 712 316 267 201 166 300
2025/20263.524 606 530 474 1.060 649 205 0 0 0 0 0 0
Totale 7.392